From allergen structure to new forms of allergen-specific immunotherapy (Q34987271)

5 August 2017

1 reference

title

From allergen structure to new forms of allergen-specific immunotherapy (English)

1 reference

5 August 2017

1 reference

1

Rudolf Valenta

1 reference

5 August 2017

Dietrich Kraft

2

1 reference

5 August 2017

1 December 2002

1 reference

Current Opinion in Immunology

5 August 2017

1 reference

5 August 2017

14

1 reference

5 August 2017

6

1 reference

5 August 2017

718-727

1 reference

Recombinant allergen molecules: tools to study effector cell activation

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens for immunoblot diagnosis of tree-pollen allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant Fel d.I: Expression, purification, IgE binding and reaction with cat-allergic human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Identification of Profilin as a Novel Pollen Allergen; IgE Autoreactivity in Sensitized Individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Profilins constitute a novel family of functional plant pan-allergens.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens for diagnosis and therapy of allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens for skin testing

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergen fragments as candidate preparations for allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen–allergic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Comparison of skin prick test with serially diluted wild-type and genetically engineered recombinant Der f2

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

In vitro and in vivo responses to the recombinant bovine dander allergen Bos d 2 and its fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

A major IgE epitope-containing grass pollen allergen domain from Phl p 5 folds as a four-helix bundle

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Evolution of IgM, IgE and IgG(1-4 )antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Exposure to birch pollen in infancy and development of atopic disease in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

IgE reactivity to Api g 1, a major celery allergen, in a Central European population is based on primary sensitization by Bet v 1☆☆☆★

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Reduction of 14-16 kDa allergenic proteins in transgenic rice plants by antisense gene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Antisense-mediated silencing of a gene encoding a major ryegrass pollen allergen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Genetically engineered plant allergens with reduced anaphylactic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Genetic engineering of allergens: future therapeutic products

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Peptide-mediated immune responses in specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Immunostimulatory DNA and applications to allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Evolution in the understanding of cross-reactivities of respiratory allergens: the role of recombinant allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Measurement of IgE antibodies against purified grass-pollen allergens (Phl p 1, 2, 3, 4, 5, 6, 7, 11, and 12) in sera of patients allergic to grass pollen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Component-resolved diagnosis with recombinant allergens in patients with cherry allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens promote expression of CD203c on basophils in sensitized individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin test reactivity to 2 recombinant Aspergillus fumigatus allergens in A fumigatus-sensitized asthmatic subjects allows diagnostic separation of allergic bronchopulmonary aspergillosis from fungal sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin prick test reactivity to recombinant latex allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Skin prick test and serological analysis with recombinant group 2 allergens of the dust mites L. destructor and T. putrescentiae

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Escherichia coli expression and purification of recombinant dog albumin, a cross-reactive animal allergen.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Hev b 9, an enolase and a new cross-reactive allergen from hevea latex and molds. Purification, characterization, cloning and expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

IgE and IgG antibody responses to recombinant Alt a 1 as a marker of sensitization to Alternaria in asthma and atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Hev b 7 is a Hevea brasiliensis protein associated with latex allergy in children with spina bifida

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens Pru av 1 and Pru av 4 and a newly identified lipid transfer protein in the in vitro diagnosis of cherry allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Identification of a Hevea brasiliensis latex manganese superoxide dismutase (Hev b 10) as a cross-reactive allergen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Hev b 8, the Hevea brasiliensis latex profilin, is a cross-reactive allergen of latex, plant foods and pollen.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Cyclophilins, a new family of cross-reactive allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Allergy to mammalian proteins: at the borderline between foreign and self?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Structure and biology of stinging insect venom allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Molecular and biochemical classification of plant-derived food allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The spectrum of olive pollen allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Characterization and immunobiology of house dust mite allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Inhibition of specific IgE response in vivo by allergen-gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

A hypoallergenic derivative of the major allergen of the dust mite Lepidoglyphus destructor, Lep d 2.6Cys, induces less IgE reactivity and cellular response in the skin than recombinant Lep d 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Mutational analysis of the IgE epitopes in the latex allergen Hev b 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Antibody binding of deletion mutants of Asp f 2, the major Aspergillus fumigatus allergen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The future of antigen-specific immunotherapy of allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Rapid method for arrayed investigation of IgE-reactivity profiles using natural and recombinant allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

The cross-reactive calcium-binding pollen allergen, Phl p 7, reveals a novel dimer assembly

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900402-8

7 January 2021

10.1016/S0952-7915(02)00402-8

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12413521